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Consumers in Shock: 
How Federal Government Overregulation Led Mylan to 
Acquire a Monopoly over Epinephrine Autoinjectors 
 
By: Nicole E. O’Toole* 
I. INTRODUCTION 
 
The freedoms and opportunities the United States of America provides 
allows Americans of any gender, race, religion, ethnicity, education, 
socioeconomic status, or background to follow their dreams and achieve 
success.  Marco Rubio, the son of a bartender and a housekeeper fleeing 
the Cuban Revolution in 1956, grew up to become an attorney, published 
author, United States Senator and Presidential nominee.1  Oprah Winfrey, 
born to a single African American teenage mother living in poverty, grew 
up to be the second-richest self-made woman in the world.2  
While it is often argued that Republicans and Democrats have the same 
end goal, the most basic and foundational difference between the parties 
in present-day American politics is the way in which each party believes 
Americans are best able to achieve success.  Typically, Democrats 
promote systems such as welfare benefits in order to help citizens who 
are in a more challenging economic position. 3   On the other side, 
Republicans usually favor a more limited role of government, including 
less regulation on business and a laissez-faire free market philosophy.4  
Senior research fellow at the Mercatus Center at George Mason 
University Matthew Mitchell illustrates the idea of similar end goals of 
opposing parties as it applied to the 2008 financial bailouts: 
Despite the ideological miles that separate them, activists in the Tea Party 
and Occupy Wall Street movements agree on one thing: both condemn 
the recent bailouts of wealthy and well-connected banks. To the Tea 
Partiers, these bailouts were an unwarranted federal intrusion into the free 
                                                        
* Nicole O’Toole is a Class of 2018 Juris Doctor Candidate at DePaul University College of Law 
and Editor-in-Chief of the DePaul Business and Commercial Law Journal.  She earned a B.A. in 
Political Science and minors in Business Administration and Global Studies from Saint Mary’s 
College in 2015.  She would like to thank her parents, James and Elizabeth O’Toole, for their 
constant support. 
1 Biography, MARCO RUBIO, http://www.rubio.senate.gov/public/index.cfm/biography (last visited 
Mar. 26, 2017). 
2 Oprah Winfrey Profile, FORBES, http://www.forbes.com/profile/oprah-winfrey/ (last visited Mar. 
26, 2017). 
3 Ryan C. Fuhrmann, What are the main differences between the Republican and Democratic 
approaches to regulating the economy?, INVESTOPEDIA, 
http://www.investopedia.com/ask/answers/regulating-economy.asp  (last visited Mar. 26, 2017). 
4 Id. 
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market; to the Occupiers, they were a taxpayer-financed gift to the 
wealthy executives whose malfeasance brought on the financial crisis. To 
both, the bailouts smacked of cronyism.5 
The notion that opposing ideologies could have similar views on 
corruption could be said about the topic of this Note: the effects of the 
federal government’s role on the epinephrine autoinjector market.  Both 
Republicans and Democrats have expressed their disdain over the rapid 
price increase of epinephrine autoinjectors in recent years, and what it 
means for those in need of the life-saving drug.  Democratic Senator 
Bernie Sanders said of the issue, “Mylan’s near monopoly on the 
epinephrine autoinjector market has allowed [Mylan] to increase prices 
well beyond those that are justified by any increase in the costs of 
manufacturing the EpiPen.”6  Republican Senator Rand Paul penned an 
op-ed piece on the issue outlining his very similar frustrations: “The 
controversy over the price of the EpiPen has reached a fever pitch as 
prices have risen by more than 400% and costing up to $600 for two of 
the pens.  To fully comprehend the outrage of this price…the epinephrine 
included in the EpiPen costs less than ten dollars retail.”7  While Senator 
Sanders and Senator Paul are typically in disagreement on most major 
political stances, their shared frustration over the epinephrine autoinjector 
market shows how bipartisan the issue is. 
Proponents of the fiscally conservative point of view, such as Ann 
Coulter, have described their support for a free market economy as 
follows: “everything provided by the free market over time will become 
better and cheaper...everything provided by the government over time 
will become more expensive and worse.”8  Many Republicans like to use 
the example of the Affordable Care Act (“Obamacare”) as an example of 
a “failed” federal attempt to police the marketplace.9  Once the healthcare 
industry was regulated by the federal government, Republicans have 
argued, the cost of insurance premiums have increased the cost of 
                                                        
5 Matthew Mitchell, GEORGE MASON U. MERCATUS CTR., The Pathology of Privilege: The 
Economic Consequences of Government Favoritism, 1 (2012), 
http://mercatus.org/sites/default/files/The_Pathology_of_Privilege-Final_2.pdf. 
6 Senators Raise Concerns About Mylan’s EpiPen Price Hike, BERNIE SANDERS (Aug. 30, 2016), 
 https://www.sanders.senate.gov/newsroom/press-releases/senators-raise-concerns-about-mylans-
epipen-price-hike. 
7 Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME, 
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/. 
8 Will Dooling, Koch's Americans for Prosperity Brings Ann Coulter to Madison in a Last-Minute 
Push to Stop “Obama's Failing Agenda”, PRWATCH CTR. FOR MEDIA & DEMOCRACY (Nov. 5, 
2012, 8:59 PM), http://www.prwatch.org/news/2012/11/11842/americans-prosperity-brings-ann-
coulter-madison-last-minute-push-stop-obamas-fail.  
9 Patient Protection and Affordable Care Act, 111th Cong. (2009), H.R.3590, CONGRESS,  
 https://www.congress.gov/bill/111th-congress/house-bill/3590. 
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medical services by an estimated twenty-four percent,10 which caused a 
number of previously successful carriers to flee the market.11  Advocates 
of this theory credit the optimization of quality goods in a given market 
to healthy competition.12  As Mitchell describes it: “markets tend to be 
competitive when, most important[ly], there are no barriers to entering or 
exiting the industry.”13 
 The philosophy that federal government intervention increases 
costs and decreases options and values available to consumers can be 
analyzed across a plethora of markets.  Specifically, this Note will focus 
on the epinephrine autoinjector market.  An epinephrine autoinjector, 
more commonly known by Mylan’s brand called the “EpiPen,”14 is most 
often used for the treatment of anaphylaxis, which is a serious allergic 
reaction that may cause death.15  Today, the EpiPen is considered the 
“Kleenex” of epinephrine autoinjectors as it is estimated to control over 
ninety percent of the market share.16  From a Darwinist perspective it 
would appear that because the EpiPen controls most of the market, it 
must be the most superior product available to consumers.  However, as 
the succeeding sections will cover, this is likely not the case, and there is 
ample evidence to prove that EpiPen’s market success is largely due to 
government regulations and mandates.  This Note will also focus on the 
2014 United States District Court case JHP Pharmaceuticals v. Hospira, 
which dealt with labeling issues surrounding epinephrine autoinjectors.17  
It is quite possible that safer, more efficient, and more affordable 
versions of the EpiPen may be available to consumers today if it were not 
for these government interventions.  
                                                        
10 Brian Blase, Overwhelming Evidence That Obamacare Caused Premiums To Increase 
Substantially, FORBES (July 28, 2016), 
http://www.forbes.com/sites/theapothecary/2016/07/28/overwhelming-evidence-that-obamacare-
caused-premiums-to-increase-substantially/#36cee92946e3. 
11 Editorial: Why Obamacare failed, CHI. TRIB. (Sept. 9, 2016), 
http://www.chicagotribune.com/news/opinion/editorials/ct-obamacare-fail-health-care-insurance-
medicine-0911-jm-20160909-story.html. 
12 Matthew Mitchell, GEORGE MASON U. MERCATUS CTR., The Pathology of Privilege: The 
Economic Consequences of Government Favoritism, 3 (2014), 
http://mercatus.org/sites/default/files/The_Pathology_of_Privilege-Final_2.pdf. 
13 Id. 
14 Important Safety Information, EPIPEN, https://www.epipen.com/ (last visited Mar. 26, 2017). 
15 Chitra Dinakar, Anaphylaxis in Children: Current Understanding and Key Issues in Diagnosis 
and Treatment, US NAT’L LIBR. OF MED. NAT’L INSTS. OF HEALTH, (Jul. 20, 2012), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492692/. 
16 Ben Popken, Lawmakers Accuse Mylan CEO of ‘Rope-a-Doping’ on EpiPen Prices, NBC NEWS 
(Sept. 21, 2016), http://www.nbcnews.com/business/consumer/lawmakers-grill-mylan-ceo-fda-
epipen-price-hike-n651201. 
17 JHP Pharmaceuticals v. Hospira, 52 F.Supp.3d 992 (C.D. Cal. 2014). 
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 As this note will discuss, courts should decline to follow the 
overall ruling in JHP Pharmaceuticals v. Hospira18 because holding that 
a court is unable to decide a case based on a separate federal agency 
simply a waste of litigation.  However, courts should consider the line of 
reasoning that where there is no proof that a non-FDA approved drug is 
any less safe than an FDA-approved drug, the non-approved drug should 
not be precluded from entering the market.   
 
II. BACKGROUND 
 
This section provides background information concerning the 
economic and legal support for the conclusion that the federal 
government’s role in Mylan’s monopoly over the epinephrine 
autoinjectors has created a burden for consumers.  The first subsection 
provides a general background on epinephrine autoinjectors. 19   The 
second subsection provides a general background on monopolies.20  The 
third subsection provides a background on Mylan’s monopoly over the 
epinephrine autoinjector market, and the government’s role in the 
creation of the monopoly.21  Finally, the fourth subsection provides a 
background on JHP Pharmaceuticals and its legal implications for 
Mylan’s monopoly over the epinephrine autoinjector market.22 
 
A. Background on Epinephrine Autoinjectors 
 
 Epinephrine is used to treat anaphylaxis, a serious, systemic 
allergic reaction that is rapid in onset and can cause death.23  Epinephrine 
helps relieve the life-threatening symptoms of anaphylaxis (such 
hypotension, shock, and upper airway obstruction) via its alpha-
adrenergic effects.24  Delayed administration of epinephrine causes an 
increased risk of death; therefore it is essential for patients at risk for 
anaphylaxis to be educated regarding the appropriate administration 
technique for epinephrine autoinjector devices.25  The most notable users 
                                                        
18 Id. 
19 See infra notes 23-46 and accompanying text. 
20 See infra notes 47-57 and accompanying text. 
21 See infra notes 58-124 and accompanying text. 
22 See infra notes 125-139 and accompanying text. 
23 Brice Labruzzo Mohundro and Michael Marlan Mohundro, Important Considerations When 
Dispensing Epinephrine Auto-Injector Devices, PHARMACY TIMES, (Sept. 22, 2010), 
http://www.pharmacytimes.com/p2p/p2pepinephrine-0910. 
24 Id. 
25 Id. 
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of these devices are children with severe food allergies who may be 
inadvertently exposed to such foods at school.26 
 
1. Background on the EpiPen 
 
Presently, the leading brand of epinephrine autoinjectors in Mylan’s 
version called the EpiPen. 27   Mylan has been the subject of much 
controversy in the past few years, as the price of the EpiPen has 
drastically increased.28  Today, a pack of two EpiPens costs about $600.29  
For reference, the amount of epinephrine in the devices only cost about 
ten dollars30, and that same two-pack of EpiPens only cost consumers 
$100 in 2008.31  Most insurers only cover one pair of EpiPens each 
year.32  However, parents with children who have serious food allergies 
are usually suggested to keep one pair of EpiPens at school, one pair at 
home, and a pair for each parent to carry with them.33  Furthermore, the 
suggested shelf life for an EpiPen in 2016 is about eighteen months, 
compared to a recommended shelf life of twenty-seven months in 2002.34  
EpiPens must be kept at room temperature, meaning they cannot be left 
in a vehicle on during extremely hot or cold weather, and must be 
protected from light and water.35  If there is even a possibility an EpiPen 
has been compromised by expiration, temperature, light, or water, it must 
be thrown away and cannot be used.36  Taking into consideration all of 
the associated risks, families could be paying upwards of $2,400 out of 
pocket per year for this life-saving drug. 
 
 
                                                        
26 Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying, 
STATNEWS,  (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylan-
windgap-medical/. 
27 Id. 
28 Id. 
29 Id.  
30 Randal H. Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, 
TIME, (Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/. 
31 Anaphylactic Political Shock, WALL ST. J., Pg. A10, (Aug. 25, 2016), 
https://www.wsj.com/articles/anaphylactic-political-shock-1472078239.  
32 Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying, 
STATNEWS, (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylan-
windgap-medical/. 
33 Id. 
34 Carolyn Y. Johnson, Why EpiPens expire so quickly, WASH. POST, (Sept. 27, 2016), 
https://www.washingtonpost.com/news/wonk/wp/2016/09/27/why-epipens-expire-so-
quickly/?utm_term=.2068a5e5e357. 
35 Frequently Asked Questions, EPIPEN http://www.epipen.ca/en/about-epipen/frequently-asked-
questions (last visited Mar. 27, 2017). 
36 Id. 
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2. Alternative Proposals to the EpiPen 
 
Adrenaclick is currently EpiPen’s main, and much cheaper, 
competition, but the product is not always covered by insurance and was 
prescribed fewer than 1,000 times in the United States last year.37  CVS 
Health recently began to market on the drug’s behalf and is hoping to 
price the generic version of the drug at just $110 for a two-pack.38  Many 
drug manufacturers have proposed their plans for competing epinephrine 
autoinjectors.  Chris Stepanian, CEO of Windgap Medical, a Boston 
startup is in the process of creating a smaller, lighter epinephrine 
autoinjector, called Abiliject, could be ready for review by 2018.39  
Stepanian explained his hope for the Abiliject would make the injector 
about forty percent smaller than the EpiPen, designed to fit in a pocket.40  
He also says Windgap is working on temperature stability, “so even if 
you leave it in your car on a hot and sunny day, you don’t have to throw 
away the device.”41  Windgap’s other goals for the Abiliject are a longer 
shelf life than the EpiPen and they are hoping to make the Abiliject more 
intuitive to use.42 
As outrage continues to grow over Mylan price increases, several 
companies have proposed their ideas for alternatives for considerably 
more affordable options, such as having families obtain syringes that a 
doctor pre-fills with epinephrine. 43   The drug manufacturer Sanofi 
introduced its own version of an epinephrine autoinjector, the Auvi-Q, in 
2012.44  The Auvi-Q was novel because it was a “talking autoinjector,” in 
which the device instructed users through the entire process of 
injection.45  This aspect of the Auvi-Q was especially beneficial because 
oftentimes the person suffering an anaphylactic attack is not the one 
administering a dose of epinephrine.  The Auvi-Q allowed a friend, 
family member, teacher, co-worker, peer, or even complete stranger 
witnessing somebody who is having an allergic reaction and unable to 
                                                        
37 Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME, 
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/. 
38 Brad Tuttle, Sick of $600 EpiPen Prices? A Major Retailer Has an Alternative for Only $10, 
TIME, (Jan. 12, 2017), http://time.com/money/4632964/cvs-epipen-alternative-adrenaclick/. 
39 Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying, 
STATNEWS,, (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylan-
windgap-medical/. 
40 Id. 
41 Id. 
42 Id. 
43 Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME 
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/. 
44 Susan Scutti, Epipen Competitor Alternatives Auvi-Q Returning Soon, CNN (Oct. 27, 2016), 
http://www.cnn.com/2016/10/26/health/auvi-q-epinephrine-autoinjector-returns/. 
45 Id, 
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self-inject to help properly administer the dose of epinephrine.  However, 
Auvi-Q was recalled in 2015 amid concerns that the product was not 
delivering an accurate dosage of epinephrine.46 
While the EpiPen tackles the most basic purpose of epinephrine 
autoinjectors (to allow users suffering from an anaphylactic attack to 
administer a dose of epinephrine), many American companies have 
tremendous ideas that would specialize, fix, or perfect the current state of 
epinephrine autoinjectors. 
 
B. General Background on Monopolies 
 
The Encyclopædia Britannica’s definition for the Hasbro, Inc. board 
game “Monopoly” is a great depiction of the economic phenomenon: 
“Monopoly [is a] real-estate board game…in which the player’s goal is to 
remain financially solvent while forcing opponents into bankruptcy.”47  
As players as young as eight years old have discovered, the way to win 
the game is to acquire all of the properties possible, and leave one’s 
opponents with nothing.  This way, the winner can control what players 
do and how much they pay.  This simplistic explanation of a monopoly is 
critical to understanding the effects of Mylan having significant market 
power because they are the only – or near only – supplier of a particular 
product. 
There are typically two ways an entity acquires such economic power 
that they face little or no competition in the territories where they 
operated: by a de jure or a de facto monopoly.48  Most of the great 
American monopolies of the early nineteenth century were de jure, or 
created by the government.49  Most twentieth century monopolies were 
de facto, or created by technology, patents, and the marketplace.50  An 
example of a de jure monopoly is the United States Postal Service 
(“USPS”).  USPS has a monopoly of the letter-delivery industry that 
dates back to 1775 when Benjamin Franklin was named the first 
American Postmaster General in order to facilitate the country’s need for 
communication between army commanders, first representatives, and 
                                                        
46 Id. 
47 Monopoly Board Game, ENCYCLOPEDIA BRITANNICA (Jul. 8, 2005), 
https://www.britannica.com/topic/Monopoly-board-game. 
48 Luis Aníbal Avilés, Public Utilities And The European Union's “Services Of General Economic 
Interest”: Feudal Origins Of Their Monopoly Powers, 4 U. P.R. BUS. L.J. 76 (2012). 
49 Herbert Hovenkamp, Technology, Politics, And Regulated Monopoly: An American Historical 
Perspective, 62 TEX. L. REV. 1263, (1984). 
50 Id. 
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constituents.51  Congress protected USPS’s monopoly in 1949 when 
Congress wrote:  
Whoever establishes any private express for the conveyance of letters or 
packets, or in any manner causes or provides for the conveyance of the 
same by regular trips or at stated periods over any post route which is or 
may be established by law . . .shall be fined . . . or imprisoned . . . or 
both.52 
By contrast, true de facto monopolies are few and far between.  The 
best example of a de facto monopoly is Sirius XM Radio.  When rival 
companies XM Satellite Radio Holdings Inc. and Sirius Satellite Radio 
merged in 2007,53  the new company, Sirius XM Radio, acquired a 
monopoly over the satellite radio market.54 
Mylan’s success in the epinephrine autoinjector market is attributed to 
some government regulation, such as the FDA approval process and the 
School Access to Emergency Epinephrine Act, as later sections will 
explore.  While Mylan is not the sole supplier of epinephrine 
autoinjectors, it does control over ninety percent of the market, therefore 
it acquires a near-monopoly over the industry, rather than an actual 
monopoly.  This is not uncommon as most other industry leaders are 
near-monopolies.  These companies may not control 100% of the market, 
but they control a majority of it, so they still reap the benefits of price 
setting in a given industry. 
Such near-monopoly examples are Netflix, having over fifty-percent of 
the market share for video streaming services, and Google, having 
seventy-percent of the market share for domestic search engines.55  The 
issue then becomes whether companies gain near-monopoly status by 
their organic success in the market, such as Netflix and Google, or due to 
some sort of government intervention.  For example, many broadband 
providers and electric utility providers have geographic-specific near-
monopolies because of government contracts.  An example of this type of 
quasi-de jure near-monopoly is ComEd in the Chicagoland area.56  While 
the City of Chicago did not create ComEd to be the sole electric utility 
                                                        
51 Universal Service and the Postal Monopoly: A Brief History, USPS, (2008),  
 https://about.usps.com/universal-postal-service/universal-service-and-postal-monopoly-
history.pdf. 
52 18 U.S.C. § 1696(a) (1948). 
53 David Ellis & Paul La Monica, XM, Sirius announce merger, CNN (Feb 20, 2007), 
http://money.cnn.com/2007/02/19/news/companies/xm_sirius/index.htm?cnn=yes. 
54 Id. 
55 The Next 7 American Monopolies, BUS. INSIDER, (Nov. 18, 2010), 
http://www.businessinsider.com/the-next-7-american-monopolies-2010-11?op=1/#streaming-
movies-future-rental-monopoly-opportunity-in-the-making-1. 
56 City to Return to ComEd for Electricity Contract, ABC, (Apr. 24, 2015), 
http://abc7chicago.com/news/city-to-return-to-comed-for-electricity-contract/680651/.  
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provider, ComEd’s contract with the city interferes with other 
companies’ ability to infiltrate the market. 57   Therefore, ComEd’s 
monopoly power in Chicago is due to government intervention rather 
than organic success in the electric utility market.  Now that the general 
foundation of monopolies has been laid, a more thorough analysis of 
Mylan’s monopoly in the epinephrine autoinjector drug market may be 
done. 
 
C. Economic Background on Mylan’s Monopoly 
 
Mylan recently generated much controversy involving the massive 
price increase of their allegedly generic brand of the epinephrine 
autoinjector drug, the EpiPen.  There are two factors playing into 
Mylan’s near-monopoly on the epinephrine autoinjector drug market.  
First, the School Access to Emergency Epinephrine Act (“SAEEA”) 
enacted by Congress in 2013 requiring all elementary and secondary 
schools in a state to maintain a supply of FDA-approved epinephrine.58  
The mandated purchase of epinephrine drugs by schools and lack of 
ability for other drug companies to sell their epinephrine drugs essentially 
created a monopoly for Mylan.59  This gave Mylan the ability to hike up 
its prices, creating a burden on consumers to attain an adequate supply of 
the drug they need.  The second is the incredibly tedious United States 
Food and Drug Administration (“FDA”) approval process and subsequent 
heavy backlog of drugs awaiting approval, which makes it nearly 
impossible for alternatives to the EpiPen to get approved.60  
 
1. The School Access to Emergency Epinephrine Act 
 
The first way Mylan achieved the ability to hike up its price of the 
EpiPen is through the enactment of the SAEEA.  Mylan was under 
criticism after it was revealed that it spent $4 million to lobby congress 
for the 2013 Act.61  “The company’s profits soared twenty-two and one 
                                                        
57 Id. 
58 School Access to Emergency Epinephrine Act, 113th Congress (2014), S.1503, CONGRESS, 
https://www.congress.gov/bill/113th-congress/senate-bill/1503. 
59 Id. 
60 Sydney Lupkin, FDA Fees On Industry Haven’t Fixed Delays In Generic Drug Approvals, NPR, 
(Sept. 1, 2016), http://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-on-
industry-havent-fixed-delays-in-generic-drug-approvals. 
61 Jacob Maslow, EpiPen Maker Mylan Flees Overseas to Avoid Taxes After 2013 School Access to 
Emergency Epinephrine Act, HUFFINGTON POST, (Aug. 31, 2016), 
http://www.huffingtonpost.com/entry/epipen-maker-mylan-flees-overseas-to-avoid-taxes-
after_us_57c2b82ae4b0b01630df8490. 
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half percent between 2013 and 2015.”62  Chief Executive Officer of 
Mylan, Heather Bresch, who was behind the price raise of the EpiPen in 
2015 received a $19 million salary.63  Mylan was also under scrutiny 
because Bresch is the daughter of Democratic Senator from West 
Virginia Joe Manchin III, a member of the 113th Congress that passed the 
SAEEA.64  While Mylan’s efforts in lobbying for the SAEEA were 
suspicious, the importance of the Act is widely undisputed.  Anaphylactic 
shock is so rapidly-onset and potentially life threatening, so the need to 
act quickly is very high.65  Therefore, SAEEA is very important in order 
to ensure that schools are prepared to treat children who may go into 
anaphylactic shock.   
Just prior to SAEEA’s enactment, it was estimated that nine and one-
half percent of American children suffered from Asthma, and between 
four and six percent of American children were affected by food 
allergies; either of which can strike in an instant, and have life 
threatening consequences.66  Congress and drug companies stepped in to 
address the concern for parents of children with asthma and severe food 
allergies (among other ailments which may trigger anaphylaxis).67  In 
2012, Mylan announced the EpiPen4Schools program, providing the drug 
for free.68  To date, Mylan has given away more than 700,000 free 
EpiPens to schools nationwide.69  After Mylan’s successful lobbying 
efforts culminated in the passage of the SAEEA in 2013, it has not been 
reported that Mylan has continued to provide schools with free EpiPens.70 
Mylan’s lobby efforts to increase the availability of epinephrine 
autoinjectors in United States schools did not go unnoticed.71  “Although 
these legislative efforts were not supposed to benefit a particular 
company, the brand has such a lock on the market that when President 
Barack Obama signed the School Access to Emergency Epinephrine Act 
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in 2013, a news announcement simply called it the ‘EpiPen Law,’” an 
article in the Chicago Tribune explained in August 2016.72   
Democratic Senator Richard Durbin from Illinois introduced the 
SAEEA to the Senate on September 12, 2013.73  Officially, the Act 
“amends the Public Health Service Act…to give an additional preference 
to a state that allows self-administration of asthma and anaphylaxis 
medication.”74  The Act: 
Requires elementary and secondary schools in such a state to: (1) permit 
trained personnel to administer epinephrine to a student reasonably 
believed to be having such a reaction, (2) maintain a supply of 
epinephrine in a secure location that is easily accessible to trained 
personnel for such treatment, and (3) have in place a plan for having on 
the school premises during operating hours one or more designated 
personnel trained in administration of epinephrine.75 
These “additional preferences” included financial incentives to states 
that enact their own mandates for schools to stock epinephrine 
autoinjectors.76  Many have argued that mandating a state “maintain a 
supply of epinephrine in a secure location that is easily accessible to 
trained personnel for such treatment”77 was the golden ticket for Mylan, 
because the EpiPen was the most well-known epinephrine autoinjector 
available, so it was the optimal choice for schools.78  If schools are 
required to supply a drug that must be administered by bystanders in 
emergency situations, it makes the most sense that they would supply a 
drug that the majority of children and staff are familiar with.  “That was a 
Trojan horse,” said David Maris, a Wells Fargo analyst.79 “That was, 
‘Let’s get it in schools to help people,’ but it helps market EpiPen and 
promote it as the trusted product in schools.”80   
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R. Adams Dudley, a pulmonologist at the University of California at 
San Francisco said of the monopoly: “[Mylan’s] most brilliant maneuver, 
clearly, was giving [EpiPens] away to schools and making it the thing 
that they could say, ‘Well, the nurse knows how to use it.’”81  As 
evidenced by their decision to use EpiPens, this logic made sense to 
school administrators, nurses, and parents.  NBC News Senior Staff 
Writer Ben Popken said of the issue: “Mylan has made its crown jewel 
product ubiquitous…. What are the parents afraid of? Their child will be 
away from them, and they won't be there to use [an epinephrine 
autoinjector]…. If they can say the school nurse knows how to use an 
EpiPen; she's never seen an Adrenaclick.... It's just a fear thing.”82  The 
combination of this government intervention, the SAEEA, along with the 
complex and lengthy FDA approval process has allowed Mylan to create 
a monopoly over the epinephrine autoinjectors.  
 
2. FDA New Drug Approval Process 
 
There are two generally unchallenged facts that are important to clarify 
in order to accurately lay the foundation for a background into the FDA 
approval process: (1) a federally-regulated approval process is critical to 
ensure that patients are receiving safe drugs, and (2), because of this, 
American consumers benefit from having access to the safest and most 
advanced pharmaceutical system in the world.83  The main consumer 
watchdog for the American pharmaceutical system is the Center for Drug 
Evaluation and Research (“CDER”), a division of the FDA.84  The 
CDER’s main role is to evaluate new drugs before they can be sold, in 
order to prevent quackery and ensure that doctors and patients are 
provided with the necessary information they need to use medicines 
wisely.85 
When a new drug wants to enter the market in the United States, the 
first step is to test the drug to prove that it is safe and effective for its 
intended use.86  In order to do so, the CDER assembles an independent 
and unbiased team of physicians, statisticians, chemists, pharmacologists, 
and other scientists to review the company’s data and proposed 
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labeling.87  This CDER team does not actually test the drug itself; rather, 
it conducts research in the areas of quality, safety, and effectiveness 
standards to determine if the drug’s health benefits outweigh its known 
risks.88 
Once the drug’s quality, safety, and effectiveness standards have been 
established, the burden shifts to the drug company, or a sponsor, to 
perform laboratory and animal tests in order to determine the likelihood 
that it will be safe and effective in humans.89  From there, the company 
can begin to test the drug on humans to determine whether it is safe when 
used to treat a disease and whether it provides a real health benefit.90  The 
need for an agency to regulate the drugs available in the American 
market to consumers is paramount in order to ensure that Americans are 
not unknowingly consuming harmful drugs.  
 
i. Generic Drug Approval Process 
 
Many new drugs are frequently under patent protection during 
development, and oftentimes throughout the approval process.91  This 
patent protects the company or sponsor’s investment in the drug’s 
development by giving them the sole right to sell the drug while the 
patent is in effect.92  A patent usually guarantees market exclusivity for a 
drug for twenty years.93  Additionally, this also incentivizes companies to 
undergo expensive research and design costs since they are likely to 
recoup the cost through utilizing their patents.94  In an article on patent 
protection strategies and market exclusivity in the pharmaceutical 
industry, leading scholars found that “skyrocketing research costs have 
resulted in an increased dependence on market exclusivity as a means of 
maintaining growth and profitability.”95  Without a patent system, such as 
the one the United States currently employs, it is likely many companies 
would steal the formulas of newly-approved drugs and manufacture and 
sell them at a much lower cost.  This would create a risk for a black 
market, the sale of unapproved drugs, and the overall safety of the drugs 
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consumers are able to purchase.  That is why once the patent, or some 
other period of exclusivity, on a brand-name drug expires, manufacturers 
can then apply to the FDA to sell generic versions of the drug.96  The 
purpose of generic drugs is to provide a safe, effective, low-cost 
alternative to American consumers.97  A generic drug is comparable to an 
“innovator” or “brand-name” drug in dosage form, strength, 
administration, quality, performance characteristics, and intended use.98 
When generic drug manufacturers apply for FDA approval, their 
applications are considered “abbreviated” because they are generally not 
required to include laboratory, animal, and clinical data to establish 
safety and effectiveness. 99   Instead, generic drug applicants must 
scientifically demonstrate that their drug is bioequivalent, or performs in 
the same manner as the brand-name drug.100  As of February 27, 2017, 
the FDA held that one way scientists can determine bioequivalence is by 
measuring the time it takes the generic drug to reach the bloodstream in 
twenty-four to thirty-six healthy volunteers.101  The generic drug must 
deliver the same amount of active ingredients into a patient’s 
bloodstream in the same amount of the time as the brand-name drug in 
order to be approved.102  Due to these very stringent requirements, as of 
July 1, 2016, the FDA had 4,036 generic drug applications awaiting 
approval and the median time for the FDA to approve a generic drug is 
forty-seven months. 103   As of 2011, more than seventy percent of 
prescriptions filled in the United States were for generic drugs.104  By 
comparison, the European Medicines Agency (Europe’s version of the 
FDA) has just twenty-four generic drugs waiting approval.105   
The extreme backlog of drugs waiting FDA approval is not by chance, 
however.  Many companies have been trying to create a generic brand of 
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epinephrine auto-injectors at a lower price than EpiPen.106  In March 
2016, generics giant Teva Pharmaceuticals’ generic version of EpiPen 
was rejected by the FDA and that its launch would be significantly 
delayed. 107  Adamis Pharmaceuticals Corporation proposed an 
alternative to the EpiPen, an epinephrine injection Pre-filled Single Dose 
Syringe (“PFS”) product, whose approval was delayed  by the FDA in 
June of 2016.108  Mylan too has expressed a desire to manufacture a 
generic version of the EpiPen.109  Mylan has said it will offer a $300 
generic version at some point in 2017, however, because Mylan also 
makes the brand-name product, it won’t have to wait in line behind other 
pending generics.110 
 
ii. Generic v. Brand-Name Drug Labeling Issues 
 
In 2011 the Supreme Court of the United States of America ruled that 
generic drug makers could not be held liable for failing to warn patients 
about the risks of their products because the companies had no control 
over what the warning labels said.111  In the 2011 case PLIVA v. Mensing, 
two similar cases from lower courts were consolidated.112  Both cases 
involved consumers who brought suit against generic drug 
manufacturers, alleging their long-term use metoclopramide (a drug used 
to treat heartburn) caused them to develop tardive dyskinesia 
(involuntary movements of the tongue, lips, face, trunk, and 
extremities).113  The plaintiffs argued brand-name drug makers have a 
responsibility to change a label whenever they discover new important 
information about a drug, and generic manufacturers are required to 
follow suit.114  However, in delivering the opinion of the court, Justice 
Thomas wrote, “it is beyond dispute that the federal…regulations that 
apply to brand-name drugs…are meaningfully different than those that 
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apply to generic drug[s]…. [I]t is the special…regulation of generic 
drugs that allowed the generic drug market to expand, bringing more 
drugs more quickly and cheaply to the public.”115  This 2011 decision 
split along ideological lines and has been highly scrutinized and praised 
by various parties.116  Proponents of the ruling appreciate the tradition of 
limiting the barriers generic drug manufacturers must pass through in 
order to bring more drugs quickly and cheaply to the market to service 
the needs of those consumers who cannot wait and cannot afford brand-
name drugs.117  Opponents of the ruling argue it increases the risk of 
harm to consumers due to inadequate warnings on generic drugs.118 
 In an op-ed piece for Fox News Health, Dr. Jennifer Brokaw, a 
practicing emergency physician for over fifteen years and founder of 
C2it, wrote about how she once inadvertently used a generic brand of an 
epinephrine drug that she was unfamiliar with.119  When she injected the 
drug she gave the patient ten times the amount of epinephrine than she 
had intended to because she assumed the generic brand was diluted, and 
it was not.120  This creates an issue as to whose negligent action caused 
the graver harm: the generic drug’s lack of labeling warning users that it 
is not diluted, or the doctor’s failure to check? 
This “labeling” issue is directly related to children’s use of epinephrine 
autoinjector drugs.  Many children with serious allergies are taught to use 
the EpiPen, and are often given prescriptions strictly for the use of 
EpiPens, and not a generic or substitute brand, because they know how to 
use EpiPens should they ever go into anaphylactic shock.121  Proponents 
of policies such as this argue limiting children’s use of epinephrine 
autoinjectors to the EpiPen will limit a child’s risk for using the drug the 
wrong way.122  Opponents of these policies argue this increases the 
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demand for, and thus the price of, EpiPens, making it unaffordable to 
many consumers.123 
As previously mentioned, the concern for the lack of generic 
competition in the epinephrine autoinjector market encompasses 
bipartisan support.  Five United States Senators, Richard Blumenthal (D-
CT), Charles Grassley (R-IA), Rob Johnson (R-WI), Amy Klobuchar (D-
MN), and Patrick Leahy (D-VT), wrote to the FDA on August 24, 2016, 
inquiring as to why generic versions of the EpiPen had been subjected to 
additional questioning by the FDA and had not yet been approved.124  
This only furthers the contention that the current system is broken.  The 
incredible backlog (of both generic and brand-name) drugs awaiting FDA 
approval has increased both the risks and prices for consumers. 
The combination of these two government regulations – the FDA 
approval process and SAEEA – created an enormous problem for the 
very consumers these regulations intended to protect.  By mandating that 
all schools purchase FDA-approved epinephrine drugs, and by creating 
an invasive and complex approval process for epinephrine drugs, the 
government has essentially allowed Mylan to obtain a monopoly over the 
drug.  This has enabled Mylan to skyrocket its prices making the life-
saving drug very unaffordable.  
 
D. Legal Background on Generic Drug Alternatives 
 
While Mylan, epinephrine autoinjector drugs, and generic drug 
alternatives have been the subject of much litigation in the United States 
legal system, this Note will focus on the 2014 United States District 
Court case JHP Pharmaceuticals v. Hospira.125  However, it is first 
imperative to understand the nature of recent case law before JHP, in 
respect to the changes to healthcare law after the Obama administration.  
On March 23, 2010, President Barack Obama signed into law the 
Patient Protection and Affordable Care Act (“ACA”), which included an 
approximately 900-page law relating to sweeping modifications to the 
health care system as a whole.126  The law’s numerous provisions also 
brought important changes to particular aspects of the highly regulated 
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pharmaceuticals industry, specifically impacting the world of brand and 
generic drug products. 127   The Biologics Price Competition and 
Innovation Act of 2009 (“BPCIA”) within the ACA was meant to 
rearrange the landscape for biologic product innovators and companies 
seeking to market follow-on biologic products.128  BPCIA attempts to 
balance the interests of innovators in recouping their large investment in 
research, testing, and regulatory approval of innovative biologic 
products, with the public’s interest in faster market entry and reduced 
prices for competing follow-on biologics.  BPCIA created a new 
regulatory pathway, by which the FDA could approve a biologic product 
as “biosimilar to” a “reference product” 129 that was itself approved under 
the full, traditional pathway under the FDA. 130   Through this new 
pathway, Congress established procedures to control and streamline 
patent litigation between the biosimilar applicant and the reference 
product, triggered by the filing of an application under the new 
abbreviated pathway. 
On May 5, 2015, Amgen, Inc. (“Amgen”) filed an emergency motion 
for an injunction to prevent Sandoz, Inc. (“Sandoz”) from marketing, 
selling, or importing into the United States ZARXIO®, its biosimilar 
product.131  The Northern District of California then issued a panel 
opinion on July 21, 2015.132  The parties each filed petitions for en banc 
review of aspects of that opinion.133  In its opinion, the Federal Circuit 
extended the injunction through September 2, 2015.134  On October 15, 
2015 Amgen officially filed suit against Sandoz for the requested 
injunction.135  The case involved the first and only approved biosimilar 
product, Sandoz’s drug called Zarxio (a filgrastim product that helps the 
body make white blood cells after receiving cancer treatments), which 
referenced Amgen’s filgrastim drug called Neupogen in order to be 
approved.136  The Northern District of California ruled that BPCIA's 
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notice of commercial marketing provision is mandatory and can only be 
given after FDA licensure of a biosimilar.137 
On March 21, 2016, Amgen filed a brief opposing 
Sandoz’s request that the Supreme Court overturn the Northern District 
of California’s ruling that BPCIA’s notice of commercial marketing 
provision is mandatory and can only be given after FDA licensure of a 
biosimilar product.138  Amgen filed a certiorari cross-petition asking that 
should the Court decide to review the commercial marketing ruling, it 
should also review and overturn the Northern District of California’s 
ruling that the patent dance information exchange procedures of the 
BPCIA are optional.139  
This legal background sets the stage for the other factors that were 
going on with the law and healthcare industry in general regarding the 
many changes that occurred during the Obama administration.  The 
ACA, BPCIA, and case law filed during these administrative changes are 
important to note when analyzing the JHP Pharmaceuticals opinion. 
 
III. JHP PHARMACEUTICALS V. HOSPIRA OPINION 
 
 In JHP Pharmaceuticals v. Hospira, 140  Plaintiff JHP 
Pharmaceuticals, LLC (“JHP”), manufacturer of epinephrine injectable 
products, brought suit against Defendants Hospira, Inc. and American 
Regent, Inc. (“Hospira”), a competitor alleging misleading labeling.  As 
previously discussed, labeling is critical to the manufacturing and selling 
of drugs.  This is because companies sacrifice a much greater cost to 
obtain “brand-name” drug status as opposed to “generic” drug status, 
which is reflected in the price companies can sell their products at.  
Therefore, as this section will discuss, the JHP opinion further 
complicates Mylan’s monopoly over the epinephrine autoinjector market.  
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A. Facts of the Case 
 
JHP submitted a New Drug Application (“NDA”) for its one-milliliter 
and thirty-milliliter injectable epinephrine products to the FDA under the 
brand name “Adrenalin.”141  On December 7, 2012, the FDA granted JHP 
approval to market and sell the one-milliliter version of Adrenalin.142  
JHP alleged that it invested millions of dollars in complying with the 
FDA approval process.143  JHP also alleged, and Hospira did not dispute, 
that Hospira was engaged in the business of selling injectable epinephrine 
products, which were not FDA-approved. 144   The bulk of JHP’s 
complaint alleged that Hospira misled the public in four different ways: 
(1) by representing that their products were FDA-approved when they 
were not, (2) by advertising their products as “safe” and “effective,” (3) 
by misleading as to the legality of their products, and (4) by misleading 
the public into thinking that JHP’s product is more dangerous than the 
generic brands.145  JHP asserted the claims against Hospira for each of 
the aforementioned reasons as in violation of the Lanham Act,146 which 
forbids false or misleading advertising.147  
 
B. Court’s Holding 
 
 The United Stated District Court held JHP’s claim that the 
competitor’s packaging was misleading by saying their non-FDA 
approved injectable epinephrine products were safer than the JHP’s 
product was not viable.  The court wrote:  
[JHP’s] fundamental argument with regard to FDA approval is that it is a 
sort of ‘Good Housekeeping Seal’ for pharmaceuticals: it is the 
government's imprimatur on a product, indicating quality, safety, and 
desirability. Although some drugs may be lawfully sold without FDA 
approval, if a product has been approved, consumers may take some 
assurance that it has been properly tested and meets the agency’s 
minimum quality standards. This makes an FDA-approved product a 
more attractive product, whether at the wholesale, retail, or end user 
level. But it can also be expensive to get approval for a drug, so a 
company that chooses to invest in getting approval may operate at a 
competitive disadvantage if other companies can falsely represent to the 
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public that their unapproved products are FDA-approved. Thus, 
representations that a drug is approved when it is not undermine the 
Lanham Act’s public policy goals both by confusing consumers and by 
enabling unfair competition by producers who have not bothered to get 
FDA approval.148 
The court dealt with JHP’s four allegations regarding the various 
arguments that Hospira misled the public, in four different ways.149  
Regarding the first instance in which JHP asserts Hospira misled the 
public, the court held that there is a large difference between a company 
making an overtly false statement and, merely misleading in context.150  
Regarding the second instance in which JHP asserts Hospira misled the 
public, the court held that the issue was not that Hospira chose to market 
their product as “safe” or “effective,” rather, that Hospira overtly misled 
the consumer by labeling their product as “FDA-approved” when it was 
not. 151   Regarding the third instance in which JHP asserts Hospira 
mislead the public, the court held this was a claim with regard to legality 
requirements that is within the primary jurisdiction of the FDA.152  
Finally,  the fourth way in which JHP asserts Hospira misled the public 
was by omitting from the labeling of their product certain injection 
location and adverse reaction information.153  JHP’s product must carry 
this labeling as apart of its FDA approval requirements.154  However, JHP 
alleges that such labeling misleads the public into thinking that JHP’s 
product is more dangerous than the generic brands. 155   The court 
dismissed this claim because the Lanham Act requires a showing of facts 
regarding the labeling that JHP did not properly plead.156   
 
IV. ANALYSIS 
 
A. Policy Implications and Legal Analysis 
 
In JHP Pharmaceuticals v. Hospira JHP argued Hospira mislead the 
public by not including on their packaging and labeling all of the 
warnings that JHP was required to include under the terms of the FDA 
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approval.157  Therefore, JHP alleged, Hospira created the impression that 
their product was less safe than JHP’s because it came with more 
warnings, when in fact, JHP believed, the opposite was true because 
JHP’s drug was approved by the FDA and Hospira’s was not.158  The 
court dismissed this claim because they believed JHP did not show that 
this message was actually transmitted to the consumer, and because JHP 
did not successfully prove that because the FDA did not approve 
Hospira’s product it was somehow less safe.159  If Hospira’s product was 
actually found to be less safe than JHP’s, then the misleading labeling 
claim would have succeeded.  Therefore, the claim was dismissed.160  
While the court never determined whether or not Hospira’s drug was 
“safe,” their failure to determine that Hospira’s drug was any less safe 
was in itself an endorsement of non-approved drugs.  If the court was 
truly concerned that Hospira was somehow trying to trick the public, it 
would have found for JHP.  Further, if the court had found that Hospira’s 
conduct was in someway unsafe to American consumers, it would have 
done something to prevent Hospira from continuing this harmful conduct. 
With respect to the surviving clams, the court reiterated the Supreme 
Court decision that the Lanham Act is a discrete regulatory scheme, with 
neither statute precluding claims made under the other.161  The court 
analyzed JHP’s surviving allegations with this in mind.162  With respect 
to Hospira’s alleged misrepresentations of FDA approval, the court found 
no preclusion, explaining that falsely representing FDA approval may 
confer a competitive disadvantage upon the approved drug.163  Thus, 
false representations of approval “undermine the Lanham Act’s public 
policy goals both by confusing consumers and by enabling unfair 
competition by producers who have not bothered to get FDA 
approval.”164 
As for JHP’s claim that the Hospira misrepresented the legality of their 
products, the court explained the evaluation of this claim “directly 
implicates the FDA’s rulemaking authority,” and required the expertise 
of the FDA to resolve.165  The court noted that “[t]he determination of 
whether a drug is ‘new,’ and whether it can be lawfully marketed under 
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the United States Federal Food, Drug, and Cosmetics Act (“FDCA”),166 
involves complex issues of history, public safety and administrative 
priorities that Congress has delegated exclusively to the FDA.”167  Unlike 
JHP’s allegations of misrepresentations of FDA approval, its allegations 
based on stations of “legality” would be precluded in the absence of prior 
review by the FDA.168 
 
1. FDA-Approved Drugs in the Market 
 
The holding in JHP Pharmaceuticals169 has tremendous impact on the 
legality surrounding non-FDA approved drugs on the market.  The 
court’s finding that there was no sufficient proof to show that an 
unregulated drug was any less safe than a regulated drug,170 speaks 
volumes to the policy issues of FDA approval.  The entire purpose of the 
FDA is to conduct research on a drug’s quality, safety, and effectiveness 
to determine whether a drug’s health benefits outweigh its known risks 
before allowing that drug to enter the market.171 In JHP Pharmaceuticals 
the court essentially found that an unregulated drug was not any less safe 
than a regulated drug.172 This could lead to questions about the actual 
purpose of the FDA.  If an unregulated drug was not necessarily any less 
safe than a regulated drug, why would any company waste the time and 
resources to gain FDA approval in the first place? 
 
2. FDA Approval Process Creates a Monopoly 
 
The FDA approval processes for new drugs create a de facto monopoly 
on approved drugs when interfering legislation, such as the SAEEA, 
complicate the market.  It is clearly important to have one consistent 
governing entity to regulate and evaluate drugs, especially a drug used by 
so many children.  However, if a federal court can undermine the 
legitimacy of an administrative agency, this presents an issue.  
Uniformity among different bodies of government is critical to the 
forefront of democracy.  However, uniformity is lacking where the 
judiciary steps in to make a definitive ruling one way or the other.  
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Courts should follow the reasoning in JHP Pharmaceuticals that where 
there is no definitive proof the non-FDA approved drug should not be 
considered any less safe.  If this reasoning is applied, companies awaiting 
FDA approval will not be punished for trying to access the market.  
Hopefully, this would allow a company to sell non-FDA approved 
epinephrine autoinjectors to consumers that desperately need the life-
saving drug. 
 
3. Economic and Legal Effects of Federal Overregulation 
 
Nonetheless, if Mylan’s competitors advertise their products as being 
as safe and as effective as the EpiPen, despite no FDA approval, this 
could help lower costs for epinephrine autoinjectors across the country.  
However, federal mandates such as SAEEA that require FDA approval 
for a very large percentage of epinephrine autoinjector sales, still feed 
into this de facto monopoly issue.  Unfortunately, a judicial ruling on this 
issue can only go so far if the regulations by other branches of 
government do not reflect the current atmosphere.  Even if the Trump 
Administration were to lift the SAEEA requirements, EpiPen has already 
accessed the system.  Even if schools were no longer required to store 
epinephrine autoinjectors, it is unlikely they would stop stocking the, 
since many students’ health still rely access to these autoinjectors.  
While hindsight is always twenty-twenty, hopefully the Mylan EpiPen 
monopoly can, at the very least, serve as a lesson to the federal 
government and advocates for overregulation.  It is evident that the 
government went too far in attempting to fix the problem of children 
going into anaphylactic shock and needing assistance with an epinephrine 
autoinjector.  Two regulations that, on their face, seem necessary (an 
FDA approval process that ensures consumers receive safe drugs and 
mandating that schools carrying epinephrine autoinjectors) thwarted the 
very success that they were trying to achieve.  Four years after the 
enactment of the SAEEA, EpiPens have quadrupled in price becoming 
nearly impossible for consumers to purchase.  Legislators should be very 
weary of the long-term effects of legislation, and continue to analyze how 
pending legislation will be affected by policies and procedures 
implemented by other branches of government.  This only reiterates the 
importance of the judiciary to answer the call and address the mistakes 
made by the legislative and executive branches. 
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V. IMPACT 
This section discusses the impact of the court’s ruling in JHP 
Pharmaceuticals v. Hospira.173  First, it explores the impact the case has 
had on the field of healthcare.174  Second, it explores the case’s impact on 
field of education.175   
 
A. Impact on Healthcare 
 
The holding in JHP Pharmaceuticals176 impacts how business works 
in the healthcare industry because ensuring that consumers have drugs 
available to them that are equally safe and affordable is critical, and, 
arguably, the most important impact of this subject.  The ways in which 
drug manufacturers can manipulate the market through favorable 
government intervention poses significant problems for consumers.  If a 
drug manufacturer has a monopoly on over ninety percent of the 
market177 then a consumer will reasonably believe that this drug is the 
most superior drug available to them.  It is one thing for a manufacturer 
to use smart business and marketing tactics, such as giving away free 
products to schools in order to increase brand recognition178, or by only 
selling the product in two-packs effectively doubling their price.179  The 
most successful companies in American history have used tactical 
business maneuvers throughout history.  Well-known companies from 
Kraft to General Mills to Proctor & Gamble have adopted this strategy.180  
However, it is an entirely different situation when a manufacturer gains 
market control because of government favorability.  Furthermore, the 
stakes are even higher when that manufacturer is creating a life-saving 
drug, rather than when a company is manufacturing macaroni and cheese 
or toothpaste. 
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B. Impact on Legislation 
 
The holding in JHP Pharmaceuticals181 impacts how overregulation of 
a field may thwart the very efforts the proposed legislation is trying to 
help.  The overregulation of epinephrine drugs essentially drove up the 
price making them nearly unaffordable for those who need them most.  
Businesses who create the best products deserve the chance to prove that 
to the market on their own, and not be overshadowed by a regulation-
induced monopoly. 
In order to ensure that consumers have access to the best, most 
efficient, most superior, and, in the case of drugs and medicine, most 
affordable products, the government should not intervene and 
overregulate the market.  In the case of the EpiPen, the government did 
so in all three branches: the executive, the legislature, and the judiciary.  
First, the FDA’s lengthy and over-complicated approval process makes it 
nearly impossible for generic drug manufacturers to create safe and 
affordable alternatives to the EpiPen.182  Second, the School Access to 
Emergency Epinephrine Act enacted by Congress in 2013 heavily 
influenced by Mylan, essentially allowed Mylan to acquire a monopoly 
over the epinephrine autoinjector market by offering financial incentives 
to states who required all schools to stock the drug, knowing full well 
that the majority of schools were only familiar with the EpiPen.183  Third, 
a federal court, failed to find that a non-approved FDA drug was any less 
safe than an FDA-approved drug,184 essentially undermining the entire 
legitimacy and purpose behind the agency.  The court, essentially deemed 
the non-FDA approved drug just as safe as FDA-approved drug, yet still 
did not make it possible for a non-FDA approved drug to enter the 
market.   
The purpose of the federal judiciary system is to evaluate laws – to 
interpret the meaning of the laws, apply laws to individual cases, and to 
decide if laws violate the Constitution.185  The beauty of the system of 
checks and balances in the United States government is that no one 
branch of government is sovereign.  If the judiciary finds a flaw within a 
law enacted by Congress when applying that law to a particular case, it 
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should further analyze whether or not the legislation is inconsistent with 
the Constitution.  While the purpose of the FDA is to ensure only safe 
drugs enter the market place, the JHP ruling found a non-FDA approved 
drug was no less safe than an FDA-approved drug.  Therefore, the court 
should not have stopped its analysis there.  The specifics of the FDA 
approval process should be called into question and analyzed by the 
federal court system.  
 
VI. CONCLUSION 
 
 In conclusion, the overregulation of the epinephrine autoinjector 
market by the federal government caused Mylan to acquire a monopoly 
on the EpiPen, increasing the cost of the product for consumers.  This 
overregulation was caused by the United States Congress in the passing 
of the SAEEA, by mandating that states must comply with this law, and 
by the over-stringent FDA approval process for alternative epinephrine 
autoinjector drugs.  Further, this problem has been exacerbated by the 
United States Federal Court system as seen in JHP Pharmaceuticals.  If 
JHP was unable to allege any facts that Hospira’s drug was either unsafe 
or ineffective and therefore the court allowed for its legal sale, then the 
federal court finding is inconsistent with the purpose of a federal 
government agency.  Drugs that are not found to be unsafe or ineffective 
should therefore be approved by the FDA, or, at the very least, be 
approved to market to consumers.   
There have been two major proposals to deal with the EpiPen 
monopoly and price surge.  Advocates on the right think the overly 
stringent FDA regulations and long approval process are to blame.  At his 
first address to a joint session of Congress, President Trump said, “our 
slow and burdensome approval process at the Food and Drug 
Administration keeps too many advances…[from] reaching those in 
need.”186 
Advocates on the left tend to think more government regulation will 
fix the problems with previous government regulation.  When she was 
running for President, Mrs. Clinton claimed the EpiPen price hikes 
showed the need for price controls, and she said she would require drug 
makers to “prove that any additional costs are linked to additional patient 
benefits and better value.”187   
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There are clearly many proposed solutions to this problem, as the 
problem itself harbors bipartisan support.  Both Republican and 
Democratic lawmakers have the same end goal: to make epinephrine 
autoinjector drugs more affordable to families who desperately need this 
life-saving drug.  Either loosening the reigns on the FDA approval 
process, or allowing for other bodies of government (such as the federal 
courts) to approve the sale of these products are viable alternatives.  This 
would allow for two products containing nearly the same ingredients, 
intended to be used for the exact same purposes, to be sold with similar 
labeling.  This would allow the free market system to naturally weed out 
the inferior of the two products based on consumer preferences.  So long 
as all of the products were considered safe and effective by the FDA, 
then the consumers could drive the market based on their preferences 
between drug manufacturers and would not be limited only by what the 
federal government allows them to choose from.  Prices would drop and 
product efficiency would increase.  
 Based on these reasons, courts should decline to follow the overall 
ruling in JHP Pharmaceuticals.188  Holding that the court is unable to 
decide cases based on a separate federal agency is simply a waste of 
litigation, which could have been used to better their products, which is 
ultimately better for society.   However, courts should consider the line of 
reasoning employed in JHP Pharmaceuticals in that where there is no 
proof that a non-FDA approved drug is any less safe than an FDA-
approved drug, the non-approved drug should not be precluded from 
entering the market because this will only increase the competition of a 
healthy market, providing more and better options for consumers. 
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